source
- Pathos AI partners with BMS and Tempus to use AI for Alzheimer’s drug developmentPathos AI announced two collaborations aimed at accelerating drug development for neurological disorders, including Alzheimer’s disease. The agreement with Bristol Myers Squibb gives the pharma co…
- Gilead’s oral ulcerative colitis drug shows significant remission in Phase 2 trialGilead Sciences reported results from a Phase 2 trial of its oral ulcerative colitis drug emvistegrast. In the study, patients took a 200 mg daily dose for 12 weeks and achieved a 23% placebo-adju…